Cardiac myofibrillar contractile properties during the progression from hypertension to decompensated heart failure

Laurin M Hanft1, Craig A Emter2, Kerry S McDonald1

  • 1Department of Medical Pharmacology and Physiology, School of Medicine, University of Missouri, Columbia, Missouri; and.

Insights

Cardiac myofilament function changes during hypertension progression. Initially, force and power increase, but later decline significantly, coinciding with heart failure onset and altered protein phosphorylation.

Area of Science:

  • Cardiovascular Biology
  • Cardiac Physiology
  • Heart Failure Pathophysiology

Background:

  • Heart failure involves complex cardiac myocyte changes, including alterations in contractility.
  • Myofibrillar contractile properties during hypertension progression to heart failure remain poorly understood.

Purpose of the Study:

  • To comprehensively assess myofibrillar functional properties from health to heart disease.
  • To investigate the time course of myofilament changes in a rodent model of hypertension and heart failure.

Main Methods:

  • Skinned cardiac myocyte preparations from Wistar-Kyoto and spontaneous hypertensive heart failure (SHHF) rats at multiple ages were used.
  • Contractile properties including force development, shortening velocity, and power output were measured.

Main Results:

  • In control rats, myofilament properties remained stable with aging.
  • SHHF rats showed increased force, shortening velocity, and power at ~12 months, followed by a significant decline at >20 months.
  • Declines in contractile properties correlated with reduced left ventricular function and onset of heart failure signs, independent of beta-myosin heavy chain levels but associated with altered protein phosphorylation.

Conclusions:

  • Myofibrillar power output undergoes significant changes during hypertension-induced heart failure progression.
  • Alterations in myofibrillar proteins and their phosphorylation are linked to contractile dysfunction in heart failure.
  • These findings identify potential therapeutic targets for improving cardiac pump function.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.1K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.2K
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
3.3K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
680
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
578
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
431